Genmab Reports Phase 2 ORRs of 75% and 67% in mCRC
Genmab reported updated results for petosemtamab plus FOLFOX/FOLFIRI, with ORRs of 75% in first-line and 67% in second-line patients. ORR was 81% in first-line left-sided tumors; the data support ongoing global Phase 3 trials.